Guangxi Medical University Cancer Hospital, Nanning, China.
People's Hospital of Wudi County, Binzhou, China.
Cancer Res Treat. 2020 Jul;52(3):789-797. doi: 10.4143/crt.2019.749. Epub 2020 Mar 5.
The purpose of this study was to evaluate the diagnostic value of soluble Axl (sAxl) in hepatocellular carcinoma (HCC) in comparison with serum α-fetoprotein (AFP).
Eighty HCC patients, 80 liver cirrhosis patients (LC), 80 patients with hepatitis B virus (HBV) infection, and 80 healthy controls (HC) were enrolled. sAxl levels were measured by an enzyme-linked immunosorbent assay, serum AFP levelswere measured by an electrochemiluminescence immunoassay. Receiver operating characteristic (ROC) curves were used to evaluate diagnostic performances.
The results show that levels of sAxl were high expression in patients with HCC (p < 0.05), varied with disease state as follows: HCC > LC > HC > HBV. Logistic regression and ROC curve analysis identified the optimal cut-off for sAxl in differentiating all HCC and non-HCC patients was 1,202 pg/mL (area under the receiver operating characteristic [AUC], 0.888; 95% confidence interval [CI], 0.852 to 0.924) with sensitivity 95.0%, specificity 73.3%. Furthermore, differential diagnosis of early HCC with non-HCC patients for sAxl showed the optimal cut-off was 1,202 pg/mL (AUC, 0.881; 95% CI, 0.831 to 0.931; sensitivity, 94.1%; specificity, 73.3%). Among AFP-negative HCC patients with non-HCC patients, the cut-off was 1,301 pg/mL (AUC, 0.898; 95% CI, 0.854 to 0.942) with a sensitivity of 84.6%, a specificity of 76.3%. The optimal cut-off for sAxl in differentiating all HCC and chronic liver disease patients was 1,243 pg/mL (AUC, 0.840; 95% CI, 0.791 to 0.888) with sensitivity 93.8%, specificity 61.9%. The combination of AFP and sAxl increased diagnostic value for HCC.
sAxl outperforms AFP in detecting HCC, especially in early HCC and in AFP-negative HCC. Combination sAxl with AFP improved the specificity for early HCC diagnosis. In summary, sAxl is a candidate serum marker for diagnosing HCC.
本研究旨在评估可溶性 Axl(sAxl)在肝细胞癌(HCC)中的诊断价值,并与血清甲胎蛋白(AFP)进行比较。
纳入 80 例 HCC 患者、80 例肝硬化(LC)患者、80 例乙型肝炎病毒(HBV)感染患者和 80 例健康对照者(HC)。采用酶联免疫吸附试验(ELISA)检测 sAxl 水平,电化学发光免疫分析法(ECLIA)检测血清 AFP 水平。受试者工作特征(ROC)曲线用于评估诊断性能。
结果显示,HCC 患者的 sAxl 水平高表达(p<0.05),并随疾病状态而变化:HCC>LC>HC>HBV。Logistic 回归和 ROC 曲线分析确定区分所有 HCC 和非 HCC 患者的 sAxl 最佳截断值为 1,202 pg/mL(ROC 曲线下面积 [AUC],0.888;95%置信区间 [CI],0.852 至 0.924),其敏感性为 95.0%,特异性为 73.3%。此外,sAxl 用于早期 HCC 与非 HCC 患者的鉴别诊断的最佳截断值为 1,202 pg/mL(AUC,0.881;95%CI,0.831 至 0.931;敏感性,94.1%;特异性,73.3%)。在 AFP 阴性的 HCC 患者与非 HCC 患者中,截断值为 1,301 pg/mL(AUC,0.898;95%CI,0.854 至 0.942),敏感性为 84.6%,特异性为 76.3%。sAxl 用于区分所有 HCC 和慢性肝病患者的最佳截断值为 1,243 pg/mL(AUC,0.840;95%CI,0.791 至 0.888),敏感性为 93.8%,特异性为 61.9%。AFP 和 sAxl 的联合检测提高了 HCC 的诊断价值。
sAxl 在检测 HCC 方面优于 AFP,尤其是在早期 HCC 和 AFP 阴性的 HCC 中。sAxl 联合 AFP 可提高早期 HCC 诊断的特异性。综上所述,sAxl 是一种诊断 HCC 的候选血清标志物。